• Home
  •  
    Regions
    • Europe
    • UK & Ireland
    • DACH
    • Nordic
    • France
    • Southern Europe
    • Benelux
    • CEE
    • Asia
  •  
    Deals
    • Buyouts
    • Venture
    • Exits
    • Refinancings
    • Build-up
    • Turnaround
    • Secondaries
    • Advanced deals search
  •  
    Funds
    • Buyout
    • Venture
    • Mezzanine
    • Debt
    • Funds-of-funds
    • Secondaries
    • Fundraising pipelines
    • Advanced funds search
  •  
    GPs & LPs
    • GP profiles
    • LP profiles
    • GP news
    • LP news
    • Sponsors search
    • LPs search
  •  
    Secondaries
    • Deals
    • Funds
    • News
    • Analysis
  •  
    People
    • People moves
    • Analysis
    • In Profile
    • Q&A
    • Videos
    • Comment
  •  
    Analysis
    • In Profile
    • Fundraising
    • Q&A
    • Comment
    • Videos
    • Podcast
    • Reports
    • Data Snapshots
  •  
    Unquote Data
    • Deals search
    • Exits search
    • Funds search
    • Sponsors search
    • Advisers search
    • LPs search
    • League tables
    • Reports
  • Sign in
  • Sign in
    • You are currently accessing unquote.com via your Enterprise account.

      If you already have an account please use the link below to sign in.

      If you have any problems with your access or would like to request an individual access account please contact our customer service team.

      Phone: +44 (0)203 741 1137

      Email: Georgina.Lawson@acuris.com

      • Sign in
     
      • Newsletters
      • Account details
      • Contact support
      • Sign out
     
  • Follow us
    • Twitter
    • LinkedIn
  • Free Trial
  • Subscribe
Unquote
Unquote
  • Home
  • Regions
  • Deals
  • Funds
  • GPs & LPs
  • Secondaries
  • People
  • Analysis
  • Unquote Data
  • You are currently accessing unquote.com via your Enterprise account.

    If you already have an account please use the link below to sign in.

    If you have any problems with your access or would like to request an individual access account please contact our customer service team.

    Phone: +44 (0)203 741 1137

    Email: Georgina.Lawson@acuris.com

    • Sign in
 
    • Newsletters
    • Account details
    • Contact support
    • Sign out
 
Unquote
  • Expansion

LSP et al. back Imcyse in €35m series-B

  • Francesca Veronesi
  • Francesca Veronesi
  • 18 June 2019
  • Tweet  
  • Facebook  
  • LinkedIn  
  • Google plus  
  • Send to  

A consortium of new and historical backers, led by LSP, has injected €35m into Belgium-based Imcyse, a developer of immunotherapies, as part of a series-B round.

LSP led the financing round of €28m ($31.6m), together with Belgian investors including Epimède, Société Régionale d'Investissement de Wallonie (SRIW), and Société Fédérale de Participations et d'Investissement (SFPI).

Existing shareholders, including Biogenosis (an investment vehicle of the Van Rompay family), Belgian VC Noshaq and University KU Leuven, also participated in the round.

Imcyse

  • DEAL:

    Early-stage

  • VALUE:

    €35m

  • LOCATION:

    Liège

  • SECTOR:

    Biotechnology

  • FOUNDED:

    2010

The startup also received a grant worth €4.6m from the Walloon region and a bank loan of €2m from Belfius.

Proceeds will facilitate clinical development of Imcyse's technology in type 1 diabetes, multiple sclerosis and other indications.

Imcyse raised €7m in a first capital round in 2012, the Belgian publication De Tijd disclosed at the time. The main investors were Biogenosis, Francois Fornieri and Jean Michel Foidart.

Company
Founded in 2010 as a spinout from the KU Leuven university, Imcyse is a developer of active specific immunotherapies for the treatment and prevention of severe chronic diseases.

Imcyse's technology platform uses modified peptides (Imotopes), which have the potential to cure and to prevent severe chronic autoimmune diseases, such as type 1 diabetes, multiple sclerosis and other autoimmune diseases, for which there is currently no cure.

People
LSP
– Jörg Neerman (partner).
Imcyse – Pierre Vandepapelière (CEO, chief medical officer).
Noshaq – Marc Foidart (COO).
Biogenosis
– Stijn Van Rompay (private investor).

Advisers
Company
– NautaDutilh (legal).
Equity
– Dentons Europe (legal).

  • Tweet  
  • Facebook  
  • LinkedIn  
  • Google plus  
  • Send to  
  • Topics
  • Expansion
  • Benelux
  • Healthcare
  • Belgium

More on Expansion

Wealth managers and financial advisers
Blackstone takes minority stake in Groupe Premium

Deal values French wealth manager at EUR 1.15bn after earlier full exit attempt saw Eurazeo target EUR 1.5bn

  • Expansion
  • 31 July 2023
Risk and compliance management services
e-Attestations aims to triple size with new Keensight backing

Keensight is investing in the risk management platform via its EUR 1bn fifth fund, which closed in 2019

  • Expansion
  • 25 July 2023
Bolt-ons and buy-and-build platforms
The Bolt-Ons Digest - 3 July 2023

Unquote’s selection of the latest add-ons with Palatine's Anthesis, Nordic Capital's Regnology, Waterland's Janssen and more

  • Expansion
  • 03 July 2023
Valentina Vitali of Limerston Capital
GP Profile: Limerston Capital anticipates higher volume but more complex M&A as market steadies

UK-based GP is seeing dealflow driven by carve-outs and buy-and-build in a market where organic multiple arbitrage is no longer a given

  • GPs
  • 07 June 2023

Latest News

Fund closes in US dollars
  • Funds
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme

Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote

  • 05 September 2023
Clinical trials and biotechnology
  • Buyouts
Permira to take Ergomed private for GBP 703m

Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO

  • 04 September 2023
Public sector software
  • Exits
Partners Group to release IMs for Civica sale in mid-September

Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017

  • 04 September 2023
EMEA Public to Private M&A
  • Investments
Change of mind: Sponsors take to de-listing their own assets

EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater

  • 04 September 2023
Back to Top
  • About Unquote
  • Advertise
  • Contacts
  • About Acuris
  • Terms of Use
  • Privacy Policy
  • Group Disclaimer
  • Twitter
  • LinkedIn

© Merger Market

© Mergermarket Limited, 10 Queen Street Place, London EC4R 1BE - Company registration number 03879547

Digital publisher of the year 2010 & 2013

Digital publisher of the year 2010 & 2013